Buscar
Mostrando ítems 1-10 de 39
Respuesta secretora de PYY1-36 y PYY3-36 en sujetos normales tras la ingesta de una comida mixta
(Elsevier para Sociedad Española de Endocrinología y Nutrición, 2008-12-25)
[Resumen] Introducción. El péptido YY (PYY) tiene 36 aminoácidos y lo sintetizan fundamentalmente las células L del intestino. El PYY aumenta tras las comidas y alcanza su nadir tras el ayuno. Tras la ingestión se liberan ...
Ghrelin and growth hormone secretagogues, physiological and pharmacological aspect
(Bentham Science, 2009)
[Abstract] The first “growth hormone secretagogues” (GHSs) were discovered by Bowers et al. in 1977. In 1996 the GHSs receptor (GHS-R 1a) was cloned. The endogenous ligand for this receptor, ghrelin, was not identified ...
Función endocrina en la obesidad
(Elsevier, 2011-08-06)
[Resumen] La obesidad se asocia con importantes anomalías en la función endocrina. La hiper insulinemia y la resistencia a la insulina son las dos alteraciones mejor conocidas, aunque sus mecanismos y su significado clínico ...
Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion
(Oxford para Endocrine Society, 2009-10-01)
[Abstract] GH plays a major role in the regulation of lipid metabolism and alterations in GH axis elicit major changes in fat distribution and mobilization. For example, in patients with GH deficiency (GHD) or in mice ...
MiR-19 family impairs adipogenesis by the downregulation of the PPARγ transcriptional network
(MDPI, 2022-12-13)
[Abstract] microRNAs (miRNAs) are a class of small endogenous RNA that play pivotal roles in both the differentiation and function of adipocytes during the development of obesity. Despite this, only a few miRNA families ...
Thyroid function alteration in obesity and the effect of bariatric surgery
(MDPI, 2022-02-28)
[Abstract] The most common endocrine disease in obesity is hypothyroidism and secondary endocrine alterations, including abnormal thyroid function, are frequent in obesity. It is unclear whether impaired thyroid function ...
Evaluation of thyroid hormone replacement dosing in morbidly obese hypothyroid patients after bariatric surgery-induced weight loss
(MDPI, 2021-08-19)
[Abstract] The most frequent endocrine disease in obese patients is hypothyroidism. To date, there are no clear data regarding what happens to the dose of levothyroxine (LT4) after bariatric surgery (BS). The objective of ...
Metabolic recovery after weight loss surgery is reflected in serum microRNAs
(BMJ Publishing Group, 2020-10-01)
[Abstract]
INTRODUCTION: Bariatric surgery offers the most effective treatment for obesity, ameliorating or even reverting associated metabolic disorders, such as type 2 diabetes. We sought to determine the effects of ...
Altered GH-IGF-1 axis in severe obese subjects is reversed after bariatric surgery-induced weight loss and related with low-grade chronic inflammation
(MDPI, 2020-08-12)
[Abstract] Endocrine disorders are common in obesity, including altered somatotropic axis. Obesity is characterized by reduced growth hormone (GH) secretion, although the insulin-like growth factor-1 (IGF-1) values are ...
Beneficial effects of bariatric surgery-induced by weight loss on the proteome of abdominal subcutaneous adipose tissue
(MDPI, 2020-01-13)
[Abstract] Bariatric surgery (BS) is the most effective treatment for obesity and has a positive impact on cardiometabolic risk and in the remission of type 2 diabetes. Following BS, the majority of fat mass is lost from ...